

---

## Editorial

---

EJPB has grown over the years and is now recognized as one of the leading journals in the field. The scientific editors are looking forward to an exciting and challenging collaboration with Elsevier, an internationally renowned scientific publisher with broad experience in the field of pharmaceutical publications.

EJPB is today 43 years old and has a large audience in over 30 countries and almost 3000 subscribers. EJPB is the official scientific journal of APV (International Association of Pharmaceutical Technology), an organization that was founded in 1954 by a visionary group of pharmacists in Germany.

As you can see, no major changes have been made with respect to the overall presentation of the journal. For reasons of convenience, the table of contents is now found on the back cover.

We have decided to increase substantially the annual number of pages in EJPB to accommodate an increased flow of submitted papers and to decrease the time from acceptance to publication. We would like to take this opportunity to thank all scientists who have con-

tributed to the success of the journal with their outstanding publications. We are also very grateful to all reviewers who have selflessly helped us over the years. The quality of the reviewing process, of course, guarantees the quality of the all scientific publications in EJPB. The editors are relying on the further efforts of our reviewers for continued improvement of the journal. Last, but not least, I also would like to thank the Editorial Advisory Board, an outstanding group of eminent scientists from all over the world. Their constructive input is essential.

In conclusion, I encourage all readers of EJPB to address letters to the editor regarding either topics of general interest or specific issues concerning recently published articles. These and, when appropriate, their replies will be published in EJPB as formal *Letters to the Editor*. Above all, EJPB is a forum for scientific discussion, exchange of opinions and constructive criticism.

Robert Gurny, Editor-in-Chief